Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

FLOT and Chemoradiation before Surgery for the Treatment of Resectable Esophageal or Gastroesophageal Junction Cancer

Trial Status: active

This phase II trial studies how well FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) and chemoradiation before surgery work in treating patients with esophageal or gastroesophageal junction cancer that can be removed by surgery (resectable). Drugs used in chemotherapy, such as 5-fluorouracil, leucovorin, oxaliplatin, docetaxel, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FLOT and chemoradiation before surgery may be an effective treatment for patients with esophageal or gastroesophageal junction cancer.